Episode Summary
Executive Summary: This episode explains seasonal affective disorder (SAD) as a recurrent subtype of clinical depression tied to seasonal patterns, especially winter. Expert Dr. Kelly Rowan outlines symptoms, prevalence, suspected causes, and standard treatments like light therapy and medication, while highlighting evidence that CBT tailored to SAD may offer longer-lasting relapse prevention. The episode also covers summer SAD, risks of unsupervised light therapy, and practical advice for mild winter blues.
Main Topics: What SAD is and how it differs from general depression: SAD is defined as recurrent major depressive disorder that appears in specific seasons, most commonly winter, and can shift to hypomania or mania in warmer seasons for some people. Symptoms, timing, and severity of winter SAD: The discussion reviews core depressive symptoms, typical onset in fall, peak severity in January and February, and the fact that episodes often last months and can include suicidal thoughts. Causes, triggers, and biological theories: Rowan explains that the exact cause is unknown, but short photoperiods, circadian phase delay, and altered melatonin rhythms are leading hypotheses for winter SAD. Treatment options: light therapy, medication, and CBT: The episode compares first-line treatments, emphasizing that CBT tailored to SAD may have durability advantages over light therapy after treatment ends. Ongoing clinical trial and biomarkers: Rowan describes a five-year NIMH-funded trial comparing CBT-SAD and light therapy, including biomarker work using pupillometry, EEG, and melatonin measures to understand mechanisms and relapse prevention. Safety, supervision, and practical guidance: Light therapy can be effective but should be supervised because dosing, device quality, and side effects matter; listeners with mild winter blues are encouraged to stay active and maintain routines. Summer SAD and seasonality beyond mood disorders: The conversation notes that some people experience summer SAD, often linked to heat, humidity, or excess light, and that seasonality may also appear in other disorders such as eating disorders and substance use.
Key Arguments: SAD is not just the winter blues; it is a recurrent form of major depressive disorder with a seasonal pattern. Winter SAD usually begins in fall, worsens in late fall/winter, and can be highly impairing for months at a time. Short daylight length is the strongest environmental trigger identified, though the exact biological mechanism remains unclear. Circadian rhythm disruption, especially a delayed melatonin phase, is a leading theory but does not explain every case. Women are diagnosed with SAD more often than men, likely reflecting broader sex differences seen in depression, though the reason remains uncertain. Light therapy is effective for many people, but dosing, device selection, and supervision are important to avoid side effects and ensure proper use. CBT adapted for SAD appears as effective as light therapy acutely and may reduce relapse in later winters, offering a durable non-pharmacologic option. Some seasonal patterns are also seen in summer SAD, which may respond better to non-light approaches such as psychotherapy, antidepressants, or thermoregulatory strategies. For mild winter blues, behavioral activation—staying active, social, and routine-based—may help even without clinical depression.
Data Points: U.S. prevalence of SAD: 6 out of every 100 people - Host opening note on how many Americans experience seasonal affective disorder Average episode duration: 5 months - Dr. Rowan describes the typical length of a SAD episode Minimum symptom threshold for diagnosis: At least 5 symptoms for at least 2 weeks - Major depressive disorder criteria applied to SAD Thoughts of death or suicide: About 30% - Proportion of people with SAD endorsing these thoughts Highest-risk months: January and February - Months when the largest proportion of SAD patients are in full depressive episodes Early symptom onset window: October to November - Timing when first symptoms often begin and intensify Photo period prevalence in Nashua, NH: 9.7% - NIH survey estimate of winter SAD near northern latitude Photo period prevalence in Sarasota, FL: 1% - NIH survey estimate showing SAD still occurs at southern latitude Women-to-men ratio in major depression: 2:1 - Used as comparison for gender disparity in non-seasonal depression Women-to-men ratio in SAD: At least 4:1 (possibly higher) - Estimated gender difference in seasonal affective disorder Light therapy remission rate in controlled trials: About 50% - Approximate proportion of participants reaching remission Current clinical trial sample: 160 adults - NIMH-funded study comparing CBT-SAD and light therapy Previous similar study sample: 177 community adults - Prior trial in greater Burlington area Circadian biomarker subgroup: About one-third - Share of SAD patients showing winter circadian phase delay on melatonin measures Seasonality in mood disorders: 10% to 20% - Estimated proportion of recurrent mood disorders with a seasonal component Latitude reference: 45 degrees north - Burlington, Vermont location mentioned when discussing normal seasonality Winter daylight on solstice: About 8 hours - Used to illustrate extreme short day length in Vermont
Pivotal Quotes: "Seasonal affective disorder, or SAD, is a form of clinical depression that's recurrent." — Dr. Kelly Rowan: Definition of SAD "About 50% of people who participate in a controlled trial of light therapy will be in remission at the end of that clinical trial." — Dr. Kelly Rowan: Explaining effectiveness of light therapy "We found apparent two winters later fewer relapses and less severe symptoms in the winter in people who got the CBT intervention relative to those who got the light therapy intervention." — Dr. Kelly Rowan: Describing longer-term benefits of CBT-SAD from prior research
Implications: Listeners should treat persistent seasonal depression as a real, diagnosable condition and seek professional assessment. For the field, CBT-SAD may become a more durable first-line option, while supervised light therapy remains important but requires careful use.